{"groups":[{"description":"Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Treatment (Crizotinib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Ineligible or Never Started"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"comment":"Primary efficacy analysis set","type":"Eligible, Treated and Mutation Status Confirmed"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"For subprotocol C2, patients were required to have MET Exon 14 deletion by the Oncomine® Assay RNA-sequencing approach, and confirmation was performed retrospectively at the DNA level using Anchored Multiplex PCR, utilizing a custom targeted DNA sequencing panel and analysis pipeline that permitted analysis of the MET exon 14 coding region and surrounding intronic sequences.","recruitmentDetails":"Subprotocol C2 was activated on May 31, 2016. Twenty patients were enrolled on EAY131-C2 between July 20, 2016, and March 16, 2020. Sixteen patients were enrolled on the basis of the results from the NCI-MATCH assay and 4 on the basis of the outside assay results."}